Alaska is currently home to 128 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Anchorage, Fairbanks, Little Rock and Bethel. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska
Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
The Clean Air Study: HEPA Purifiers to Improve Indoor Air Quality and Health in Rural Alaska Homes
NCT06534385
Recruiting
Alaska Native children experience a high burden of respiratory disease, especially those in the Yukon-Kuskokwim (YK) Delta. Studies have shown that things like wood stove use, poor ventilation, and indoor tobacco smoke exposure can lead to poor indoor air quality inside the children's homes. This leads to more frequent and more severe respiratory infections in children. In the Yukon-Kuskokwim (YK) Delta, it's common for homes to have exposure to woodstoves and tobacco use. Both of these activit... Read More
Gender:
ALL
Ages:
5 years and below
Trial Updated:
02/25/2025
Locations: Yukon Kuskowkim Health Corporation, Bethel, Alaska
Conditions: Air Pollution, Indoor
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302
Recruiting
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska
Conditions: Lymphoma, Follicular
Register for Updates
The Sequestration of Holistic Stress Management Techniques for Adults
NCT06098755
Recruiting
This remote study is intended to assist the population with access to cost-effective pastoral counseling for stress management in the workplace and every day life. In awareness of a support system, Bachelor's age 30 and older requirements were waived to accept the Bachelor's age 21-29 for verified relatives of an individual Humanitarian Veterans Association member; however, without BLOOD-QUANTUM to an individual Humanitarian Veterans Association member, the preferred Bachelor age is 30 years old... Read More
Gender:
MALE
Ages:
30 years and above
Trial Updated:
02/19/2025
Locations: Virtual Tribunal Monastery, Anchorage, Alaska
Conditions: Stress, Job
Register for Updates
A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01).
NCT06012435
Recruiting
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295
Recruiting
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska
Conditions: Urothelial Carcinoma
Register for Updates
A Study of SGN-B6A in Advanced Solid Tumors
NCT04389632
Recruiting
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedoti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska
Conditions: Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Carcinoma, Non-small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms, HER2 Negative Breast Neoplasms, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Register for Updates
STOP AF First Post-Approval Study
NCT05227053
Recruiting
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Alaska Heart Institute, Anchorage, Alaska
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
02/10/2025
Locations: Research Site, Anchorage, Alaska
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
More Outside Your Door: a Diet/physical Activity Intervention to Decrease Risk of Obesity in Alaska Native Preschoolers
NCT06303544
Recruiting
The preschool age is a crucial period of growth and an optimal time to begin to establish healthy eating and physical activity habits leading to better food and activity choices into adulthood, thereby minimizing risk for obesity-related diseases and decreasing the cardiometabolic disparities in this Indigenous population. More Outside Your Door is a multi-level, randomized, stepped-wedge intervention trial designed to reduce the disparity of childhood obesity in Yup'ik Alaska Native children by... Read More
Gender:
ALL
Ages:
Between 3 years and 5 years
Trial Updated:
01/27/2025
Locations: Alaska Native Tribal Health Consortium, Anchorage, Alaska
Conditions: Child Obesity
Register for Updates
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667
Recruiting
This Phase 2b, multicohort, open-label clinical trial (QUILT-3.055) evaluates combination immunotherapies in patients with various advanced solid tumors who have progressed following prior PD-1/PD-L1 checkpoint inhibitor therapy. The trial includes six cohorts: Cohorts 1-4: Patients who progressed after an initial response (PR or CR) to prior PD-1/PD-L1 therapy, receiving combination therapy with N-803 and a PD-1/PD-L1 checkpoint inhibitor. (Closed to enrollment) Cohort 5: Patients who progres... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Alaska Clinical Research Center, Anchorage, Alaska
Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Register for Updates